Sporos Bioventures

Tvardi Therapeutics, Inc. is a biotechnology company based in Houston, Texas, focused on developing innovative medicines for cancer, chronic inflammation, and fibrosis. Founded in 2017, the company specializes in small molecule inhibitors targeting STAT3, a regulatory protein involved in the progression of various cancers and fibrotic diseases. Tvardi's pipeline includes TTI-101, an oral small-molecule STAT3 inhibitor, and an intravenous formulation for non-cancer indications, as well as TTI-102, another oral candidate with potential in STAT3 inhibition. By addressing the underlying mechanisms of disease, Tvardi Therapeutics aims to provide effective treatments for patients suffering from diverse conditions, including breast and lung cancer, as well as chronic inflammatory and fibrotic diseases.

Asylia Therapeutics is a biotechnology company established in 2019 in Houston, Texas, specializing in innovative immune-modulating therapies for autoimmune diseases, cancer, and infectious diseases. The company focuses on a drug pipeline that aims to modulate antigen presentation to the immune system, resulting in significant anti-tumor responses in various cancer models. Asylia's therapies are designed to assist healthcare providers in treating solid tumors, including breast and colon cancer, as well as hematologic malignancies such as multiple myeloma. By transforming scientific advancements into effective medicines, Asylia Therapeutics seeks to improve treatment outcomes for patients facing these challenging conditions.

Nirogy Therapeutics is a biotechnology company focused on developing innovative small molecules that target cellular transporters to address chronic diseases, including cancer and autoimmune disorders. The company employs a transporter target platform that integrates transporter biology, structural biology, and computational chemistry to understand the underlying mechanisms of these diseases. This approach guides the design and development of new drugs while also informing strategies for patient selection. By advancing small molecules aimed at disrupting metabolic and immune mechanisms within the tumor microenvironment, Nirogy Therapeutics aims to address significant unmet medical needs in oncology and inflammation.